Stock 002675 YANTAI DONGCHENG PHARMACEUTICAL GROUP CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Stock

Equities

002675

CNE100001DP5

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 18:00:00 2024-04-25 EDT 		5-day change 1st Jan Change
13.31 CNY +1.22% Intraday chart for Yantai Dongcheng Pharmaceutical Group Co.,Ltd. +7.69% -27.39%
04-26 Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
04-11 Dongcheng Biochemicals' Unit Gets Nod to Trial Tumor Drug in Singapore MT

Financials

Sales 2023 3.28B 452M 618M Sales 2024 * 3.85B 532M 727M Capitalization 10.98B 1.51B 2.07B
Net income 2023 210M 28.98M 39.62M Net income 2024 * 460M 63.48M 86.79M EV / Sales 2023 4.61 x
Net cash position 2023 * - 0 0 Net cash position 2024 * - 0 0 EV / Sales 2024 * 2.85 x
P/E ratio 2023
72.1 x
P/E ratio 2024 *
23.8 x
Employees 2,174
Yield 2023
0.68%
Yield 2024 *
0.56%
Free-Float 63.12%
More Fundamentals * Assessed data

Chart Yantai Dongcheng Pharmaceutical Group Co.,Ltd.

Dynamic Chart

Latest news about Yantai Dongcheng Pharmaceutical Group Co.,Ltd.

Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Dongcheng Biochemicals' Unit Gets Nod to Trial Tumor Drug in Singapore MT
Dongcheng Pharmaceutical to Buy Liver Drug Rights from Affiliate for 85 Million Yuan MT
Dongcheng Pharmaceutical Unit to Buy Rights to Tumor-Detecting Drug for 63 Million Yuan; Shares Up 10% MT
Dongcheng Pharma's Singaporean Unit Gets FDA's Nod to Carry Out Trial on 68GaLNC1007 Injection MT
Yantai Dongcheng Pharma Unit Secures License for Radioactive Cargo Transport MT
Dongcheng Pharmaceutical Gets Nod to Trial Tumor Drug in China MT
Yantai Dongcheng Pharmaceutical's Unit Ties Up With Chinese Physics Institute for Electron Accelerator Development MT
Yantai Dongcheng Pharma Gets Nod to Trial Prostate Cancer Treatment in China MT
Dongcheng Pharma Forms Medical Isotopes JV With Germany’s Eckert & Ziegler MT
Qi Kang Medical Technology Co., Ltd. announced that it has received ?20 million in funding from Yantai Dongcheng Pharmaceutical Group Co.,Ltd. CI
Dongcheng Biochemicals Unit Gets Nod to Trial Prostate Cancer Drug in Singapore MT
Dongcheng Biochemicals' Unit Gets Nod to Market Dalteparin Sodium Injection MT
Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Dongcheng Biochemicals Receives Good Manufacturing Practice Certificate from Germany MT
More news

Quotes and Performance

1 day+1.22%
1 week+7.69%
Current month-2.56%
1 month-9.82%
3 months-13.63%
6 months-23.29%
Current year-27.39%
More quotes

Highs and lows

1 week
12.28
Extreme 12.28
13.47
1 month
12.11
Extreme 12.11
14.40
Current year
12.05
Extreme 12.05
19.08
1 year
12.05
Extreme 12.05
20.15
3 years
9.94
Extreme 9.94
22.98
5 years
9.94
Extreme 9.94
29.60
10 years
5.34
Extreme 5.3367
29.60
More quotes

Managers and Directors - Yantai Dongcheng Pharmaceutical Group Co.,Ltd.

Managers TitleAgeSince
Zhi Gang Luo CEO
 Chief Executive Officer 53 18-08-09
Qing Lin Liu CHM
 Chairman 53 98-12-30
Chun Ping Zhu DFI
 Director of Finance/CFO 59 98-12-30
Members of the board TitleAgeSince
Shou Yi You CHM
 Chairman 62 07-12-18
Xiao Jie Liu BRD
 Director/Board Member 42 18-01-22
Chun Xiang Lue PRN
 Corporate Officer/Principal 49 98-12-30
More insiders

ETFs positioned on Yantai Dongcheng Pharmaceutical Group Co.,Ltd.

Name Weight AuM 1st Jan change Investor Rating
LEADERSHARES EQUITY SKEW ETF - USD ETF LeaderShares Equity Skew ETF - USD
0.00% 117 M€ +1.11% -
More ETFs positioned on Yantai Dongcheng Pharmaceutical Group Co.,Ltd.

Quotes

Date Price Change Volume
24-04-26 13.31 +1.22% 13,669,420
24-04-25 13.15 +2.65% 11,701,780
24-04-24 12.81 +1.67% 9,305,689
24-04-23 12.6 +0.48% 10,942,400
24-04-22 12.54 +1.46% 13,396,220

End-of-day quote Shenzhen S.E., April 25, 2024

More quotes

Company Profile

Yantai Dongcheng Biochemicals Co., Ltd is a China-based company principally engaged in the research, development, manufacture and sales of medical drugs. The Company’s main products are categorized into active pharmaceutical ingredients (APIs), nuclear medicines, chemical drugs and traditional Chinese medicines, which include heparin sodium APIs, chondroitin sulfate, preparation products, radionuclide drugs and others. The Company distributes its products in domestic market and to overseas markets.
Sector
Pharmaceuticals
Calendar
2024-04-26 - Q1 2024 Earnings Release
More about the company

Income Statement Evolution

More financial data

Ratings for Yantai Dongcheng Pharmaceutical Group Co.,Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
13.31 CNY
Average target price
20.3 CNY
Spread / Average Target
+52.52%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

1st Jan change Capi.
YANTAI DONGCHENG PHARMACEUTICAL GROUP CO.,LTD. Stock Yantai Dongcheng Pharmaceutical Group Co.,Ltd.
-27.39% 1.51B
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+19.62% 43.34B
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+20.44% 21.96B
SANDOZ GROUP AG Stock Sandoz Group AG
+10.86% 14.09B
CIPLA LIMITED Stock Cipla Limited
+13.07% 13.64B
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+37.46% 11.43B
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-8.59% 6.86B
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6.79B
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+8.46% 5.22B
Generic Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 002675 Stock